85
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)

, , , , , , , , & show all
Pages 1425-1434 | Published online: 28 Jun 2016

References

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2015 Available from http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdfAccessed May 24, 2016
  • PartridgeMRKarlssonNSmallIRPatient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet surveyCurr Med Res Opin20092582043204819569976
  • KesslerRStahlEVogelmeierCPatient understanding, detection, and experience of COPD exacerbations: an observational, interview-based studyChest2006130113314216840393
  • RocheNChavannesNHMiravitllesMCOPD symptoms in the morning: impact, evaluation and managementRespir Res20131411224143997
  • DahlRGallagherNGreenYQVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPDEuropean Respiratory Journal201342Suppl 57
  • BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
  • Jahnz-RozykKSzepielPEarly impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational studyInt J Chron Obstruct Pulmon Dis20151061362325834420
  • D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
  • KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
  • BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
  • ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
  • MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
  • KulichKKeiningerDLTipladyBBanerjiDSymptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE studyInt J Chron Obstruct Pulmon Dis201510799425609942
  • BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
  • KenwardMGRogerJHThe use of baseline covariates in crossover studiesBiostatistics201011111719915170